Introduction
Taenia solium, the pork tapeworm, is endemic in most of the world, including most developing countries where pigs are raised. Infection of the human nervous system by T. solium larvae (neurocysticercosis) is a very common event in endemic regions, where symptomatic neurocysticercosis (NCC) accounts for approximately one-third of seizure disorders [1,2 ,3 ,4,5] and contributes to other neurological disease [6 ] .
Treatment of NCC is not a simple task. The multiple possible combinations of numbers of lesions, location (involving its relationship with surrounding structures, key in neurological pathology), size, involutive stage, and associated inflammation open a wide array of clinical pictures [7 ] . Treatment, however, faces a surprising scarcity of therapeutic tools: only two antiparasitic drugs are of use, anti-inflammatory treatment is mostly restricted to steroids, and only recently has minimally invasive surgery been added to open surgery and shunt placement as surgical options. We will review here the main concepts on disease pathogenesis and treatment, and critically discuss the existing therapeutic options.
The infection and the disease
As for many helminths, the life cycle of T. solium involves a definitive host, a carnivore, that ingests the larvae located in the flesh of the intermediary host. These larvae develop as adult tapeworms (usually one in the case of T. solium) in the intestines of the definitive host and produce infective eggs which are disseminated with the stools into the environment, to be ingested by a suitable intermediary host (a herbivore). After ingestion, the embryos in the eggs are liberated, cross the intestinal wall, reach the circulatory system, and are dispersed to the tissues where they develop into cystic larvae or cysticerci. The cycle closes when the larvae-infected flesh of the intermediate host is eaten by a carnivore predator [8] .
In the usual cycle of T. solium, man act as definitive host, harboring the tapeworm, and pigs act as intermediate hosts. Unfortunately, man can also become infected with cysticercosis by ingesting tapeworm eggs via fecal oral contamination. Resulting cysts may locate in almost any organ or tissue. In most locations they will not be noticed, but when cysts locate in the nervous system or the eye, symptoms may be not only noticeable but can also produce severe and incapacitating disease, which is sometimes lethal [9] .
Human NCC infection in endemic regions seems to be a very common event. Population serosurveys find up to 20-25% of the entire population with specific antibodies to T. solium, and computed tomography (CT) scan surveys in healthy populations find between 10 and 20% of them with brain calcifications likely representing resolved cysts [1,3
,4]. Each of these provide only a partial assessment of infection burden in a population, as many infected individuals resolve the infection and become seronegative, and of course people with brain cysts are only a subset of all infected individuals.
Whether or not NCC is a major contributor to seizures and other neurological morbidity has been questioned by some authors on the basis of the many asymptomatic infected individuals described above. However, evidence supports a major impact on the prevalence of seizure disorders. First, individuals with brain cysticercosis are a sizable subset of patients with seizures in neurological centers in endemic countries. Even in population studies, approximately 30% of cases of seizures seem to be attributable to NCC [1, 2 ]. Furthermore, treatment of viable brain cysts with antiparasitic agents results in local inflammation around the lesion and may reproduce or exacerbate the same symptomatology (hence the use of steroids), providing additional evidence of the relationship between symptoms and lesions [10] .
Another subject of discussion is the 'transient' nature of symptoms in NCC. Patients with only viable brain cysts seem to have few symptoms, which increase at the time of the degeneration of at least one of the cysts and then become less symptomatic after the parasite resolves. However, many individuals persist with viable cysts for decades, and calcified lesions may also be symptomatic even decades after the parasite has died. This may not, however, be the case in individuals with a single degenerating brain nodule, as seen in India where seizure relapses are much less common [11] .
So, although there are many asymptomatic-infected individuals with NCC in population settings, the proportion which becomes symptomatic is large enough to contribute to the burden of neurological disease in endemic regions, because of the chronicity of the disease [10] .
Types of neurocysticercosis and their particularities
In order to understand the general treatment directions and particular approaches in NCC, one first needs to consider that NCC may result in many different clinical presentations, depending on number, location, and stage of the lesions. This had been mentioned in the old British literature [12, 13] , but became particularly clear after the introduction of CT. As early as 1986, Estanol et al. [14] differentiated between 'benign' and 'malignant' NCC on the basis of its intraparenchymal or extraparenchymal location, which in general reflects very well a marked difference in evolution and prognosis. The most recent advances in imaging and syndromic characterization have led to better understanding of the spectrum of clinical presentations.
Intraparenchymal brain cysticercosis
Parenchymal disease is mostly characterized by seizures. Invasive embryos reach the brain through terminal arteries and grow in the grey matter. By growing towards the inside, they become surrounded by brain parenchyma and grow as rounded, cystic, fluid-filled vesicle structures upto their usual size of 1-2 cm. Cysts in the brain cortex may actually grow towards the surface and subarachnoid space of the convexity of the brain, but they still behave as intraparenchymal lesions. Intraparenchymal parasites follow an involutionary course: after surviving for years as viable cysts, they are detected and attacked by the host's immune system, lose their survival equilibrium and die. Their contents become gradually cloudy and colloidal, the cysts shrink, and finally resolve to leave a residual calcified scar [15] .
A common presentation of intraparenchymal NCC, particularly frequent in the Indian subcontinent (where most cases of NCC present like this) is a single, degenerating intraparenchymal brain cyst. It presents at younger ages and carries a very benign prognosis [16, 17] .
Other less frequent presentations are cysticercotic encephalitis, in which multiple (hundreds) small intraparenchymal cysts are inflammed causing severe intracranial hypertension [18] , and massive, nonencephalitic cysticercosis, in which again hundreds of intraparenchymal cysts survive with minimal evidence of inflammation, mostly causing occasional seizures [19] .
Extraparenchymal neurocysticercosis
Parasitic larvae located in the subarachnoid space or in the basal cisterns follow a progressive course with growth and invasion of neighboring spaces. In this process, they lose their form and become membranous extensions; this infiltration commonly results in obstructive hydrocephalus and intracranial hypertension, compromising the life of the patients [20 ] . Cysts in the ventricles can directly block the flow of the cerebrospinal fluid (CSF), also resulting in hydrocephalus. Parasites located in the Sylvian fissure tend to grow disproportionately and may reach several centimeters, behaving as a benign, slowgrowing tumoral mass [21] .
As a gross summary, intraparenchymal NCC usually follows a benign course and is characterized by seizures, whereas extraparenchymal NCC is progressive, associated with intracranial hypertension, and sometimes lethal. The latter is also very difficult to treat, requiring multiple courses of antiparasitic therapy (see below).
Main lines and goals of treatment
Symptomatic NCC cases are usually individuals with seizures, headaches, intracranial hypertension, or other neurological symptoms. Management involves adequate symptomatic measures and, when appropriate, antiparasitic treatment or surgery. Antiparasitic therapy in NCC is never an urgent action and it seems clearly appropriate to wait until the patient is stable and without symptoms to initiate antiparasitic treatment. Appropriate symptomatic management should be instituted first. Symptomatic therapy is key and involves analgesics, antiepileptic drugs, anti-inflammatories (mostly steroids), and management of intracranial hypertension when present [10] .
In patients with seizures secondary to NCC, antiepileptic drug (AED) therapy should be administered as for any other cause of epilepsy. Seizures usually respond very well to first-line AED monotherapy with either phenytoin, carbamazepine, or valproate [22] . Increased intracranial pressure arises from perilesional edema (in which case it usually responds well to oral corticosteroids, which may be required long term) or obstructive hydrocephalus. In the case of the latter, the insertion of a ventriculoperitoneal shunt may be required. Shunt obstruction is a common event because of the parasite cellular debris, and the increased protein levels in CSF which are usual in basal subarachnoid NCC [23] . Concomitant use of corticosteroids has been reported to decrease the frequency of shunt obstruction [24] .
Antiparasitic agents, either albendazole (ABZ, 15 mg/kg/ day p.o. for 8-15 days) or praziquantel (PZQ, 50-75 mg/ kg/day p.o. for 15 days), are effective in killing live cysticerci. ABZ is currently the drug of choice because of slightly greater efficacy, better availability, and lower cost [25, 26] . A short course of three doses of 75-100 mg/ kg of PZQ in the same day (every 2 h) was reported in Mexico in 1996 [27] , but its efficacy appear to be lower in patients with multiple cysts.
Antiparasitic treatment of patients with viable or degenerating cysts seems to be associated with better seizure evolution [25, 28] . On the other hand, the use of antiparasitic treatment in NCC was for a long time a matter of intense controversy. Between the second and the fifth days of antiparasitic therapy, patients usually have an exacerbation of neurologic symptoms, attributed to local inflammation due to the death of the larvae. Apparently, the destruction of live parasite cells exposes antigens and triggers an intense local inflammatory reaction which exacerbates symptoms and can be lethal because of intracranial hypertension. For this reason, antiparasitic treatment should be given under hospital conditions, simultaneously with corticosteroids to control edema and intracranial hypertension [10] . Co-administration of corticosteroids reduces blood levels of PZQ [29] ; however, this is not thought to be clinically relevant at usual doses of administration.
The partial efficacy of existing antiparasitic regimes (only 60-70% of cysts die and only 30-40% of patients are free of viable brain cysts after an initial course of treatment) [25, 26, 28] forces the search for better regimes. Increased doses of ABZ, up to 30 mg/kg/day, have been tried with success by some groups [30, 31] , but the lack of a thorough safety assessment in the published literature conveys caution with this approach, as ABZ is associated with some frequency with increased liver enzymes, usually transient, and decreased blood cell counts. More recently, the combined use of ABZ and PZQ for NCC has been reported and seems a very promising alternative [32,33 ,34] . A large trial comparing ABZ and combined ABZ plus PZQ is currently under way in Peru.
The use of steroids along with antiparasitic treatment is also poorly studied. Published regimes vary enormously in terms of the drug of choice, doses, and length of treatment. Most authors use a moderate amount of dexamethasone (usually 0.1 mg/kg/day) from the day before the onset of antiparasitic treatment until the end of antiparasitic treatment.
The role of surgery was for a long time limited to shunt placement and open craniotomies to excise cysts from the ventricles, Sylvian fissure, or more rarely, large cysts in other locations, with the risks and drawbacks of open cranial surgery [35 ] . The advent of minimally invasive neurosurgery (neuroendoscopy) has greatly changed this view and now the recommended management of intraventricular cysts is neuroendoscopical extraction, and fenestration of the anterior wall of the third ventricle during the same procedure may save the need for a shunt, although no controlled data are yet available for this claim [36] . Its use for other NCC locations such as those in basal cistern lesions has been reported, but more extensive experience seems to be required before assessing the risks and benefits.
Animal models for treatment
Naturally infected pigs can be purchased with some facility in endemic countries and provide a suitable treatment model [37] . Infected pigs are identified by peasants by palpation of the lower surface of the animal's tongue, where cysts frequently locate. This simple screening method detects heavily infected animals and thus the chance of these having brain cysts is higher [38] . Drawbacks of this model include interanimal variability in cyst numbers and lack of certainty on whether degenerating cysts are because of treatment or whether they were already involutioning before therapy.
Experimental infections in pigs can be done orally [39] or by local injection of infective oncospheres (intramuscular oncosphere assay, IMOA) [40] . The oral model has a much more variable cyst yield, and the IMOA assay does not follow the natural intestinal route.
Comparative treatment trials can be performed in naturally or experimentally infected pigs by adequate group allocation, enough sample size to detect efficacy differences, and appropriate logistic procedures including separating groups to avoid ingestion of the other drugs after excretion in stools. Cyst degeneration is not immediate but results from attack by the pig cellular immune system [41] , and thus a period of several weeks after treatment should be allowed to evaluate the effects of the tested therapies.
Prevention and control
Beyond the standard measures to avoid fecal oral contamination and appropriate raising of, active control interventions have been tried with variable results, mostly using mass human chemotherapy. A large-scale elimination program in Peru found no transmission in 101 of 104 intervened villages after 1 year with a combined scheme (CWGP 2011, unpublished data) using repeated rounds of mass human chemotherapy with niclosamide followed by identification of taeniasis cases with coproantigen detection, and mass porcine chemotherapy with oxfendazole, plus vaccination of pigs with TSOL18, a highly effective vaccine produced at the University of Melbourne in Australia [39, 42] . From here onwards, the control tools used should be made affordable and less costly, and tested in different geographical and cultural scenarios towards the goal of widespread elimination and potential eradication.
Conclusion
Despite its importance as a cause of neurological disease in most of the world, treatment of NCC faces a notable scarcity of tools and controlled efficacy data. Antiparasitic treatment seems of benefit in most cases but its efficacy is suboptimal. Combining ABZ and PZQ may improve cysticidal efficacy without compromising safety. On the surgical side, neuroendoscopy appears as the most important advancement in NCC management. 
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